Chargement en cours...
SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
In XLH, excess circulating FGF23 causes hypophosphatemia, rickets, lower limb deformity, and impaired growth and mobility. An active-controlled, phase 3 trial (CL301; NCT02915705) showed treatment with burosumab, a fully human monoclonal antibody against FGF23, resulted in significantly greater impr...
Enregistré dans:
| Publié dans: | J Endocr Soc |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7208884/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.196 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|